James Church, MD
Colon & Rectal Surgery · New York, NYNPI 1487698726
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,320 of the $2,168 with a category attached, or 60.9%. Takeda Pharmaceuticals U.S.A., Inc. accounts for 61.9% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2022 at $1,453 and has fallen 89.2% since, to $156 in 2025.
Across 16 payments — averaging $135.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Johnson & Johnson$220
- Medtronic$156
- AbbVie$127
- Ferring Pharmaceuticals Inc.$121
- Myriad Genetic Laboratories, Inc.$85
- plus $117 from 2 others
What the payments were for
- Consulting fees$1,32061%
- Food & beverage$84839%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $1,342 |
| Johnson & Johnson(2 entities) | 6 | $220 |
| Medtronic | 1 | $156 |
| AbbVie | 2 | $127 |
| Ferring Pharmaceuticals Inc. | 1 | $121 |
| Myriad Genetic Laboratories, Inc. | 1 | $85 |
| Covidien LP | 2 | $78 |
| Intuitive Surgical | 1 | $39 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,168 in reported general payments places this provider in the 55th percentile of 177 colon & rectal surgery providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other colon & rectal surgery in New York
- Sanghyun KimNew York$154K
- Mehraneh JafariNew York$50K
- Jeffrey MilsomNew York$42K
- David SchwartzbergNew York$26K
- Richard WhelanNew York$23K
- Alessandro FicheraNew York$20K
- Juliet RayNew York$17K
- Cary AaronsNew York$16K
- Debbie BakesNew York$15K
- Parul ShuklaNew York$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.